Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Hydroxyamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamphetamine SCHEMBL125440 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| (S)-P-Hydroxyamphetamine SCHEMBL256809 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL219712 | 0.98 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL221649 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL28160718 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| (S)-P-Hydroxyamphetamine SCHEMBL9707065 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL219710 | 0.98 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL11539011 | 0.98 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL221291 | 0.98 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL221647 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3130 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-3870170-B1 | TREATMENT OF PRESBYOPIA AND MYDRIASIS WITH PHENTOLAMINE | OPUS GENETICS INC (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20240415738-A1 | DEVICES AND METHODS FOR CORNEA TREATMENT | D&D Biopharmaceuticals, Inc. (US) | 2024-12-19 | — | — | US | claimed |
| EP-3413872-B1 | NON-INVASIVE OCULAR DRUG DELIVERY INSERT TECHNOLOGY | UNIV DE COIMBRA (PT) | 2024-10-02 | — | — | EP | claimed |
| WO-2024163315-A2 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | DEVORE DALE (US) | 2024-08-08 | — | — | WO | claimed |
| US-20240252446-A1 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | SUSTAINED DRUG DELIVERY LLC | 2024-08-01 | — | — | US | claimed |
| US-20240216334-A1 | METHODS AND COMPOSITIONS FOR TREATING MYDRIASIS, GLAUCOMA, AND OTHER OCULARCONDITIONS | OPUS GENETICS, INC. | 2024-07-04 | — | — | US | claimed |
| EP-0311383-B1 | MONOCLONAL ANTIBODY TO METHAMPHETAMINE, PREPARATION OF THE SAME, ASSAY METHOD AND ASSAY KIT OF METHAMPHETAMINE | UBE INDUSTRIES, LTD. (JP) | 1993-10-06 | — | — | EP | claimed |
| EP-0126684-B1 | DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS | MERCK & CO. INC. (US) | 1991-08-28 | — | — | EP | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| EP-0059057-A1 | Treatment of diarrhoea | BEECHAM GROUP PLC (GB) | 1982-09-01 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4186184-A | Selective administration of drug with ocular therapeutic system | ALZA CORPORATION (US) | 1980-01-29 | — | — | US | claimed |
| US-3968245-A | Sympathomimetic topical and percutaneous administration with halogenated promoters | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | claimed |